EGF-like module containing mucin-like hormone-like 2 (ERM2) binding agents and methods of use thereof

Anti-EMR2 antibodies and CARs provide targeted therapy for AML by selectively binding to EMR2, enhancing the specificity and efficacy of CAR T-cell therapy for acute myeloid leukemia treatment.

WO2024238565A1PCT designated stage expired Publication Date: 2024-11-21VOR BIOPHARMA INC

Patent Information

Application Number
PCT/US2024/029308
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-14
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current therapies for acute myeloid leukemia (AML) lack effective targeted approaches due to the complexity of the disease and the challenge of developing comprehensive treatments, with CAR T-cell therapy showing promise but requiring improved specificity and efficacy.

Method used

Development of anti-EMR2 antibodies and chimeric antigen receptors (CARs) that selectively bind to EMR2, utilizing specific amino acid sequences and complementarity determining regions (CDRs) to target EMR2-expressing cells, including hematopoietic malignancies like AML, through monoclonal, humanized, or camelid antibody formats, and their integration into immune cells for therapeutic application.

Benefits of technology

The anti-EMR2 antibodies and CARs demonstrate selective binding and targeting of EMR2-expressing cells, enhancing therapeutic efficacy in treating AML by specifically engaging immune cells to recognize and attack cancerous cells, thereby improving treatment outcomes for patients with hematopoietic disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024029308_21112024_PF_FP_ABST
    Figure US2024029308_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides antibodies, antigen binding fragments thereof, and fusion proteins, including chimeric antigen receptors, that target EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2). Also provided herein are methods of using such antibodies, antigen binding fragments thereof, and fusion proteins, for treating hematopoietic malignancies or hematological diseases (e.g., acute myeloid leukemia, myelodysplastic syndrome).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Introduction and expression of foreign genetic material in epithelial cells

    US4868116A

  • In vivo introduction and expression of foreign genetic material in epithelial cells

    US4980286A

  • Liposomes with enhanced circulation time

    US5013556A

  • Retroviral gene transfer into diploid fibroblasts for gene therapy

    US5219740A

  • Method of testing the dose accuracy of a medication delivery device

    US5308341A

Cited By

  • Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof

    WO2025030010A1